The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- FSR receives confirmation from the Department of Labor ensuring patient access to FMLA for participation in clinical trials
- Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
- 12 Years of Sarcoidosis Advocacy
- Sarcoidosis…and the Sound of Silence
- FSR Expands Scientific Advisory Board with 14 New Experts